Composite Interceptive Med Science aims to create a novel genre of therapeutic solutions. It is based on creating composite pharmacology, capable of targeting interception of disease, along its continuum, even before the development of a diagnosable disease state or moving towards its final progression. The approach is not to replace current pharmaceutical standard of care, but to enable it scientifically and help its established approach, to optimise clinical outcomes. This is possible by a complex computational approach, combining genomic sequencing data from current medical research, related knowledge on pathophysiology of disease states, applying current rationale of pharmaceutical research and exploration of different systems of medicine.
Conventional reductionist approach of drug discovery has restricted the landscape for innovative therapeutics. Highly focussed single target molecules are easily scalable and the synthetic processes being linked to quick clinical outcomes are easily regulated. . New research evidence shows, current form of targeted treatment as having multiple collateral effects, not easily justifiable with the cost of these treatments. CIMED offers a new Polymolecular approach to looking at medical therapeutics for the future. Here, diseases are modelled and a composite approach to management is created.
CIMED is one of the first companies to work towards creating a composite pharmacology that can create Interceptive Medicine. It will be the first to put into practice, the knowledge of genetic predisposition to disease and help the individual to intercept or delay the onset or progression of diseases using CIMED drugs.